Mast Cells in Irritable Bowel Syndrome and Ulcerative Colitis: Function Not Numbers Is What Makes All the Difference
Theoharis C. Theoharides
0
1
2
3
0
T. C. Theoharides Department of Internal Medicine, Tufts University School of Medicine and Tufts Medical Center
,
Boston, MA 02111, USA
1
T. C. Theoharides Sackler School of Graduate Biomedical Sciences, Tufts University
,
Boston, MA 02111, USA
2
T. C. Theoharides (&) Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Integrative Physiology and Pathobiology, Tufts University School of Medicine
, 136 Harrison Avenue,
Boston, MA 02111, USA
3
T. C. Theoharides Department of Psychiatry, Tufts University School of Medicine and Tufts Medical Center
,
Boston, MA 02111, USA
Data obtained from animal and human studies support the existence of mast cells (MC) in the gastrointestinal (GI) tract, where they are considered important for the control of luminal parasites and possibly other microorganisms. MC are also implicated in food allergies, GI inflammation, and functional GI diseases, including irritable bowel syndrome (IBS) [1]. MC density may be increased in inflammatory bowel disease (IBD) and IBS, although such studies have yielded variable and sometimes contradictory results, likely due to methodological problems such as sampling issues, poorly characterized MC identification methodology, and lack of adequate documentation of disease correlates. There is no question that MC numbers are likely to be easier to identify and count in lesional areas as they may be present in IBD.
-
MC density in the terminal ileum had previously been
reported to be significantly increased in patients with IBS,
even though MC abundance only correlated weakly with
IBS symptoms, and, in some cases, a decreased density of
colonic c-kit-positive in IgE- or IgG-stained MC, was
reported [2], even though IgE- or IgG-staining is not an
index of MC activation.
In the paper by Choi et al. [3] published in this issue of
Digestive Diseases and Sciences, the authors analyzed
intestinal MC density in: (a) diverse patient cohorts,
including diarrhea predominant-IBS (D-IBS), ulcerative
colitis (UC) in remission, mild UC, and in healthy controls;
(b) random colonic biopsies; (c) different colonic
segments; and (d) mucosal MC and lamina
propria/intra-epithelial T lymphocytes. The results are important because
MC number was significantly increased in 97.6 % of
D-IBS patients, intra-epithelial lymphocytes (IEL) were
increased in 92.8 %, and lamina propria lymphocytes
(LPL) were increased in 81.9 %. Moreover, even though
the numbers of immune cells were even higher in some
post-infectious (PI)-IBS patients, the remaining D-IBS
patients had a significantly higher number of these cells
compared with controls. Immunochemically identified
were tryptase-positive MC and CD3-positive T cells (and
not for all lymphocytes, as the authors stated).
All publications to date, including the one by Choi et al.
[3], did not report MC activation, which, according to
some, is more important than actual numbers [4].
For instance, tryptase staining underestimates the
number of degranulated MC, since released secretory granule
tryptase does not stain. One way to identify degranulated
MC is to stain for c-kit (CD117), the surface MC receptor
for stem cell factor. Nevertheless, since mediator secretion
can also occur without degranulation [5], MC activation
can best be identified either by ultrastructural appearance
or by qPCR measurement of histidine decarboxylase or
tryptase gene expression.
Unfortunately, patients with IBS or UC have not been
evaluated for potential triggers, especially their stress
status, since stress induces numerous pathological alterations
[6], including MC-dependent increased intestinal
permeability [7]. A brief period of restraint stress activated
mucosal MC and disrupted the gut-blood barrier, as
evidenced by breakdown of tight junctions in enteric villi [8].
Corticotropin-releasing hormone (CRH), secreted from the
paraventricular nucleus of the hypothalamus in response to
stress, activates the hypothalamic-pituitary adrenal (HPA)
axis leading to secretion of cortisone that generally has
anti-inflammatory effects. Instead, CRH secreted outside
the CNS has pro-inflammatory actions [9], apparently
through activation of MC [10]. For instance, CRH was
reported to increase mucosal barrier permeability,
dependent on MC activation [11].
The trigger(s) for MC proliferation and activation may
be different in IBS than it is in UC. Stress is important in
IBS as discussed above, whereas stress and infections may
be more important in UC pathogenesis. For instance,
chronic stress disrupted hindgut barrier function, inducing
MC-dependent bacterial adhesion and intestinal
inflammation [12].
Summary and Future Directions
MC appear to be increased in IBS[ (PI)-IBS [UC as
compared to controls. This finding alone suggest that there
is some common underlying pathogenesis involving MC
that may depend on the degree of GI inflammation present.
Unfortunately, it is hard to sample the entire gut and use
the same preservation and staining techniques to make this
approach useful diagnostically. Future studies should focus
on GIMC function by investigating gene expression of
unique MC mediators in whole-mount random biopsies or
in laser-captured mucosal MC. Given sufficient biopsy
tissues, such mediators could also be quantitated using
Western blot analysis. Patients should be better
characterized and phenotyped for the presence of other related
diseases, such as chronic fatigue syndrome, fibromyalgia,
mastocytosis, bladder pain syndrome/interstitial cystitis,
who share symptoms and other attributes with IBS [13],
and may contribute their own pathological characteristics.
Inhibition of mucosal MC may be an effective
therapeutic approach since they can also super-stimulate
activated T cells [14]. Use of select natural flavonoids, such
as luteolin, hold promise for further development since
they can inhibit MC and T cell function [14].
(...truncated)